Chemomab announces publication of peer-reviewed article on CCL24

Chemomab Therapeutics announced the publication of a peer-reviewed research article describing how CCL24 is a key driver of the fibrotic and inflammatory disease processes that result in primary sclerosing cholangitis, or PSC, a rare disease of the bile ducts that has no FDA-approved treatments and is often fatal. The publication also includes preclinical studies showing that CM-101, Chemomab’s CCL24-neutralizing antibody, is effective in interrupting these fibro-inflammatory processes and could potentially improve patient outcomes. CM-101 is currently in a Phase 2 trial for the treatment of PSC. The research article, CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis, was published in the June edition of JCI Insight.